The independent firm Datamonitor reports at least 64 firms, 80% of them small biotechs, are engaged in developing therapeutic cancer vaccines. The report said much of the research is trial and error and still at an early stage, and "translating the basic knowledge into clinical practice has proved difficult."

Full Story:

Related Summaries